Press Release: From News&Views April 2019: The Biologics Price Competition and Innovation Act (BPCIA) of 2009 created an FDA approval pathway for biosimilars that aimed to expanded patient access to these more affordable therapies.
AMCP writes to request your veto on House Bill 435 which implements an exception process for coverage of a drug removed from a formulary at the previous cost sharing level. Imposing government mandated restrictions on formularies as outlined in the bill could have the unintended consequence of raising the overall cost of health care coverage for patients.
From April 2019 News & Views: AMCP and the AMCP Foundation last month recognized a group of thought leaders for their significant contributions to the profession of managed care pharmacy.
From April 2019 News & Views: Four student pharmacists from the University of Washington School of Pharmacy took top honors in the Academy of Managed Care Pharmacy (AMCP) Foundation 19th National Student Pharmacist Pharmacy & Therapeutics (P&T) Competition.
From April 2019 News & Views: The Biologics Price Competition and Innovation Act (BPCIA) of 2009 created an FDA approval pathway for biosimilars that aimed to expanded patient access to these more affordable therapies. But formidable barriers, including concerns about safety and efficacy among prescribers and state laws on substitution and interchangeability, have hindered biosimilar adoption.
From April 2019 News & Views: James Kenney took the helm as 2019-2020 AMCP President at the Annual Meeting last week in San Diego. The following is a lightly edited version of his inaugural address at the General Session.